Micro-fluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode joint detection

Through the microfluidic chip with dual-mode combined detection of CRISPR-Cas12a and immunofluorescence visualization, the accuracy and convenience of tissue PD-L1 detection are solved, and efficient detection of PD-L1 positive CTCs in the peripheral blood of NSCLC patients is achieved. Supports non-invasive multiple sampling and diagnostic and efficacy monitoring of immunotherapy.

CN119034834APending Publication Date: 2024-11-29SHANGHAI CHEST HOSPITAL

Patent Information

Application Number
CN202411236001.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the prior art, there are problems with accuracy and convenience in tissue PD-L1 detection, especially in the case of internal and external heterogeneity and dynamic changes in PD-L1 expression, it is difficult to accurately predict PD-L1 expression in NSCLC patients through non-invasive methods and Effectiveness of immunotherapy.

Method used

Using a microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode detection, circulating tumor cells were captured through Epcam antibody, and quantitative analysis was carried out for PD-L1 aptamer and fluorescently labeled antibodies to achieve PD-L1 positive CTCs. Efficient capture and detection.

Benefits of technology

Accurate detection of PD-L1-positive CTCs in the peripheral blood of NSCLC patients is achieved, supporting non-invasive multiple sampling, assisting in the diagnosis and efficacy monitoring of immunotherapy drugs, and improving the prediction accuracy of PD-L1 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119034834A_ABST
    Figure CN119034834A_ABST
Patent Text Reader

Abstract

The invention discloses a micro-fluidic chip based on CRISPR-Cas12a (Clustered Regularly Interspaced Short Palindromic Repeats-Cas12a) and immunofluorescence visualization dual-mode joint detection. The chip is composed of three layers, the bottom layer is a microscope glass slide, the middle layer is a PDMS block with a microchannel and a glass slide, and the uppermost layer is a polystyrene transparent shell for protecting the chip; a microarray is arranged in a microchannel in the chip, microsites coated with Epcam antibodies are distributed on the surface layer, the antibodies and CTC are combined and adhered to the chip, and efficient capture of the circulating tumor epithelial cells is achieved. The chip is matched with a PD-L1 positive CTCs detection kit for use. According to the micro-fluidic chip for jointly detecting the PD-L1 positive circulating tumor cells of the peripheral blood of the NSCLC patient based on the CRISPR-Cas12a and the immunofluorescence visualization dual mode, provided by the invention, the PD-L1 expression of the NSCLC patient and the monitoring and prognosis of the curative effect of immunotherapy can be conveniently and accurately predicted in a clinical non-invasive manner.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a microfluidic chip in the biomedical field for detecting PD-L1 positive circulating tumor cells in the peripheral blood of NSCLC patients, and in particular to a microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection. Background Art

[0002] Tumor is a disease that is very harmful to the human body. Tumors are divided into benign tumors and malignant tumors. Malignant tumors are also called cancer, which is a disease that people are afraid of.

[0003] In recent years, immunotherapy, as an emerging cancer treatment, has brought hope of life to many patients with advanced cancer. Currently, the most widely used method is to use targeted monoclonal antibodies against regulatory immune checkpoint molecules that inhibit T cell activation, among which drugs that block programmed death protein-1 and programmed death ligand protein-1 (PD-1 / PD-L1) are the main representatives.

[0004] At present, tissue PD-L1 detection is still mainly used in clinical practice to assist immunotherapy, but there are many problems with tissue PD-L1 detection, such as (1) detection technology. Different PD-1 / PD-L1 inhibitors have corresponding PD-L1 detection methods, but the antibodies and technologies used in each test are different, resulting in different settings for PD-L1 expression levels. At the same time, the settings for PD-L1 expression levels for different tumor types are also different. This is a big problem and challenge for result interpretation. (2) Biological aspects. Such as intra-tumor and inter-tumor heterogeneity. (3) Tissue source. Such as cytological specimens, archived specimens and fresh specimens, primary sites and metastatic lesions, etc. (4) PD-L1 expression has the characteristics of dynamic changes, fluctuating, up-regulated or down-regulated with time and treatment response. For some patients in the late stage who cannot obtain tissue, there is no way to judge the PD-L1 expression status and thus choose a treatment method.

[0005] Therefore, more accurate and convenient PD-L1 detection methods are urgently needed in clinical practice to assist immunotherapy. Summary of the invention

[0006] The purpose of the present invention is to provide a dual-mode combined detection of PD-L1 in peripheral blood of NSCLC patients based on CRISPR-Cas12a and immunofluorescence visualization + The CTCs microfluidic chip solves the problems existing in the existing technology. Through more accurate and convenient detection methods, it is convenient for clinicians to accurately predict the PD-L1 expression of NSCLC patients and monitor the efficacy and prognosis of immunotherapy in a non-invasive manner.

[0007] In order to achieve the above-mentioned object, the present invention provides a microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode joint detection, wherein the microfluidic chip is composed of three layers, the bottom layer is a microscope slide, the middle layer is a PDMS block with microchannels and a slide, and the top layer is a polystyrene transparent shell for protecting the chip; the microchannels inside the chip are provided with a microarray, and the surface layer is arranged with microsites coated with Epcam antibodies, and the antibodies are combined with CTCs and adhered to the chip to achieve efficient capture of circulating tumor epithelial cells.

[0008] Furthermore, the chip is prepared by treating the surface of a PDMS block having microchannels and a glass slide with plasma, then embedding and bonding one side of the chip on the bottom glass slide, and finally connecting a polystyrene transparent shell to protect the chip, the shell comprising a cylinder connecting the inlet and outlet holes.

[0009] Furthermore, the chip is used in conjunction with a PD-L1 positive CTCs detection kit; the kit includes a PD-L1 aptamer reagent and a CD45 / PanCK / PD-L1 antibody combination labeled with fluorescein.

[0010] Furthermore, in the chip, the modified Epcam antibody captures a single intact CTC cell, and the cell fluorescence image is obtained by immunofluorescence staining and localization; the specific aptamer is incubated in the channel to recognize and bind to the PD-L1 membrane protein on the surface of the CTC or the free PD-L1 protein, and the microfluidic end releases the initiator chain, which causes a primer exchange reaction under the action of the enzyme, generates an amplification product, and activates the CRISPR / Cas12a cleavage reporter group, which is finally quantified by a fluorescence spectrometer.

[0011] Furthermore, when the chip is used, the aptamer chain is first hybridized with the promoter chain to prepare an experimental probe, and then the CRISPR / Cas12a system is used to analyze the target.

[0012] Furthermore, the analysis target is to inject the aptamer / promoter probe solution into the chip, incubate it with circulating epithelial tumor cells separated by the microfluidic system for different times, take the incubated mixture, add the CRISPR-Cas12a reaction system, and measure the fluorescence intensity of the reaction solution.

[0013] Furthermore, the chip, when in use, also includes identifying the cells captured in the chip by immunofluorescence staining.

[0014] Furthermore, the identification process is as follows: adding cell fixative to the chip, incubating at room temperature, washing the chip with buffer, removing residual cell fixative, taking PanCK-FITC, CD45-APC and PD-L1-Cy5.5 direct-labeled antibodies respectively, mixing them with the dye diluent and injecting them into the chip, incubating in a wet box away from light, and then washing the chip, aspirating the nuclear dye and mixing it with the buffer and injecting it into the chip for incubation in the dark, and then washing the chip, using a fluorescence microscope to acquire images along the designated focus surface, and performing cell image acquisition, counting and analysis.

[0015] Furthermore, the chip, through a fluorescence microscope, observed that the circulating epithelial cells had complete cell morphology under bright field, and the nuclear-cytoplasmic ratio was consistent with the characteristics of tumor cells; the cell nucleus was blue and the cell membrane was green under the fluorescence microscope, that is, PanCK expression was positive, indicating circulating epithelial tumor cells; the cell nucleus was blue and the cell membrane was orange, that is, CD45 expression was positive, indicating white blood cells; the cell nucleus was blue and the cell membrane was green and red fluorescence, indicating PD-L1 + CTCs.

[0016] Furthermore, the chip also includes drawing a receiver operating curve when in use to explore the sensitivity and specificity of the microfluidic analysis system in capturing and CRISPR / Cas12a in quantitatively diagnosing the positive expression of PD-L1 in non-small cell lung cancer.

[0017] The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection provided by the present invention has the following advantages:

[0018] The present invention provides a microfluidic chip and its application in detecting PD-L1 (programmed death ligand protein 1) positive CTCs (circulating tumor cells) in the peripheral blood of NSCLC (non-small cell lung cancer) patients. The microsites coated with Epcam (epithelial cell adhesion molecule) antibodies are arranged on the surface of the microarray inside the chip, and the antibodies bind to CTCs and adhere to the chip to achieve efficient capture of circulating epithelial tumor cells. In addition, a PD-L1 positive CTCs detection kit is provided. The detection of CTC PD-L1 protein expression level can well solve the difficulties encountered by tissue PD-L1, is not limited to tissue sampling, and can achieve multiple non-invasive sampling, assist immunotherapy drug companion diagnosis, and can not only be used for immunotherapy, but also can be used as a tumor marker to assist surgery, radiotherapy (chemotherapy) and neoadjuvant chemotherapy in prognosis evaluation, efficacy monitoring and disease progression monitoring.

[0019] This invention targets PD-L1 for the first time +A dual-mode detection method was designed for CTCs. PD-L1 is an important indicator for the diagnosis and prediction of immunotherapy for NSCLC patients. The dual-mode microfluidic chip was prepared to efficiently and conveniently enrich and detect PD-L1. + CTCs can facilitate clinical non-invasive and accurate prediction of PD-L1 expression and immunotherapy efficacy monitoring and prognosis in NSCLC patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of the microfluidic system channel structure and CTC capture process.

[0021] Figure 2 Schematic diagram of the hairpin amplification system for targeting, release and catalysis using the NUPACK analysis method to simulate the secondary structure of oligonucleotides and duplexes.

[0022] Figure 3 This is the electrophoresis representation diagram of Western blotting (WB).

[0023] Figure 4 The fluorescence spectra obtained by the reaction system established in the present invention under different reagent combination conditions.

[0024] Figure 5 A is the expression level of PD-L1 protein in normal lung epithelial BEAS-2B and 6 NSCLC cell lines. Figure 5 B is a graph showing the expression levels of PD-L1 in different NSCLC cell lines, PD-L1 positive and negative control cells by BioINK staining.

[0025] Figure 6 Fluorescence intensity and PD-L1 + A graph showing a linear increase in the logarithmic value of CTCs concentration.

[0026] Figure 7 Schematic diagram of the chip capturing the staining patterns of WBC and CTC in the peripheral blood of NSCLC patients.

[0027] Figure 8 Example images of CTC staining for PD-L1(-) and different degrees of PD-L1(+) in the peripheral blood of NSCLC patients captured by the chip.

[0028] Fig. 9 Capture and quantitative analysis of PD-L1 by CRISPR / Cas12a for integrated microfluidic analysis system + CTCs and diagnostic performance prediction diagram. DETAILED DESCRIPTION

[0029] The specific implementation of the present invention will be further described below in conjunction with the accompanying drawings.

[0030] The present invention provides a microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode joint detection. The microfluidic chip consists of three layers, the bottom layer is a microscope slide, the middle layer is a PDMS (polydimethylsiloxane) block with microchannels and a slide, and the top layer is a polystyrene transparent shell for protecting the chip; the microchannels inside the chip are provided with a microarray, and the surface layer is arranged with microsites coated with Epcam antibodies, and the antibodies are combined with CTCs (circulating tumor cells) and adhered to the chip, so as to achieve efficient capture of circulating epithelial tumor cells.

[0031] Preferably, the chip is prepared by plasma treating the surface of a PDMS block having microchannels and a glass slide, then embedding and bonding one side of the chip onto the underlying glass slide, and finally connecting a polystyrene transparent shell to protect the chip, the shell comprising columns connecting the inlet and outlet holes.

[0032] The chip is used in conjunction with a PD-L1 (programmed death ligand protein-1) positive CTCs detection kit; the kit includes a PD-L1 aptamer reagent and a CD45 / PanCK / PD-L1 antibody combination labeled with fluorescein.

[0033] In this chip, the modified Epcam antibody captures single intact CTC cells, and the cell fluorescence image is obtained by immunofluorescence staining. Then, the channel is incubated with a specific aptamer to recognize and bind to the PD-L1 membrane protein on the CTC surface or the free PD-L1 protein, and the microfluidic end releases the initiator chain, which causes a primer exchange reaction (PER) under the action of the enzyme, generates an amplification product, and activates the CRISPR / Cas12a cleavage reporter group, which is finally quantified by a fluorescence spectrometer.

[0034] Circulating tumor cells (CTCs) are a collection of heterogeneous cells, including epithelial, mesenchymal, and mixed epithelial-mesenchymal CTCs. EpCAM (Epithelial Cell Adhesion Molecule) and CSV (Cell Surface Vimentin) can be used as targets for isolating epithelial and mesenchymal subtypes of CTCs, respectively.

[0035] Epcam antibody, also known as epithelial cell adhesion molecule monoclonal antibody. EpCAM is a transmembrane glycoprotein that acts as a homophilic receptor reactive molecule between intestinal epithelial cells (IECs) and mucosal intraepithelial lymphocytes (IELs), serving as the first line of defense in the immune barrier against mucosal infections. It plays an important role in the proliferation and differentiation of embryonic stem cells, and can also upregulate the expression of FABP5, MYC, and cyclins A and E. EpCAM is seen in most epithelial tumors, while most non-epithelial tumors do not show EpCAM expression. Used in combination with other markers, EpCAM can be used as an auxiliary means to determine the epithelial origin of tumors, such as distinguishing lung adenocarcinoma from mesothelioma.

[0036] The CRISPR / Cas system is an acquired immune system of prokaryotes that is used to resist the invasion of exogenous genetic elements present in bacteriophages or plasmids. It is a defense mechanism present in most bacteria and all archaea to eliminate foreign plastid or bacteriophage DNA. It is now widely used in genetic engineering. The core of this system consists of two parts: CRISPR sequence and CAS (CRISPR associate system). Among them is the CRISPR / Cas12 system, which mediates DNA cleavage at the far PAM end by a single RuvC domain, and the tag gene is Cas12. Some are mediated by a single crRNA, such as CRISPR / Cas12a; some are mediated by crRNA and tracrRNA (or mediated by fused sgRNA alone), such as CRISPR / Cas12b. Cas12a is a multifunctional protein containing a double-stranded DNA binding domain and a nuclease domain. The nuclease domain has DNA endonuclease activity and can non-specifically cut DNA. Cas12a (also known as Cpf1), as a type of nuclease mediated by a single crRNA, can specifically recognize and cleave double-stranded DNA (dsDNA) targets with PAM (5-TTTN-3' or 5'-TTN-3), breaking the DNA double strands and generating sticky ends. The recognition and cleavage of single-stranded DNA (ssDNA) targets are independent of the PAM sequence.

[0037] When the chip is used, the aptamer chain is first hybridized with the promoter chain to prepare the experimental probe, and then the CRISPR / Cas12a system is used to analyze the target.

[0038] The analysis target is to inject the aptamer / promoter probe solution into the chip, incubate it with circulating epithelial tumor cells isolated by the microfluidic system (i.e., epithelial circulating tumor cells CTC isolated with EpCAM as the target) for different times, take the incubated mixture, add the CRISPR-Cas12a reaction system, and measure the fluorescence intensity of the reaction solution.

[0039] Before the chip was validated for use, it was also used to detect the protein expression level of PD-L1 in cells by immunoblotting (WB) and the fluorescence intensity of PD-L1 in normal lung epithelial cells and different NSCLC cell lines by BioINK (bio-ink) reagent staining, so as to verify the feasibility of the chip method in the later stage of modeling.

[0040] When in use, the chip also includes identifying the cells captured in the chip by immunofluorescence staining, and the process is as follows: adding cell fixative to the chip, incubating at room temperature, washing the chip with buffer, removing residual cell fixative, taking PanCK-FITC, CD45-APC and PD-L1-Cy5.5 direct-labeled antibodies respectively, mixing them with the dye diluent and injecting them into the chip, incubating in a wet box away from light, and then washing the chip, aspirating the nuclear dye and mixing it with the buffer and injecting it into the chip for incubation in the dark, and then washing the chip, using a fluorescence microscope to acquire images along the designated focus surface, and performing cell image acquisition, counting and analysis.

[0041] Under a fluorescence microscope, the chip can be observed under bright field to show that circulating epithelial cells have complete cell morphology, and the nuclear-cytoplasmic ratio is consistent with the characteristics of tumor cells; under a fluorescence microscope, the cell nucleus is blue and the cell membrane is green, which means PanCK expression is positive, indicating circulating epithelial tumor cells; the cell nucleus is blue and the cell membrane is orange, which means CD45 expression is positive, indicating white blood cells; the cell nucleus is blue and the cell membrane is green and red fluorescence, indicating PD-L1 + CTCs.

[0042] When used, the chip also includes drawing a receiver operating characteristic (ROC curve) to explore the sensitivity and specificity of the microfluidic analysis system in capturing and CRISPR / Cas12a in quantitatively diagnosing the positive expression of PD-L1 in non-small cell lung cancer (NSCLC).

[0043] The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection provided by the present invention is further described below in conjunction with the embodiments.

[0044] It should be noted that these examples are merely illustrative and should not be construed as limiting the present invention. Where specific techniques or conditions are not specified in the examples, conventional experimental conditions or conditions recommended in the manufacturer's instructions are used. Where the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0045] Unless otherwise specified, the terms used in the present invention have the general meanings in the field to which the present invention belongs.

[0046] Example 1

[0047] A microfluidic chip based on dual-mode joint detection of CRISPR-Cas12a and immunofluorescence visualization, the microfluidic chip consists of three layers, the bottom layer is a microscope slide, the middle layer is a PDMS block with microchannels and a slide, and the top layer is a polystyrene transparent shell that protects the chip; the microchannels inside the chip are equipped with a microarray, and the surface is arranged with microsites coated with Epcam antibodies. The antibodies bind to CTCs and adhere to the chip, thereby achieving efficient capture of circulating tumor epithelial cells.

[0048] Preferably, the chip is prepared by plasma treating the surface of a PDMS block having microchannels and a glass slide, then embedding and bonding one side of the chip onto the underlying glass slide, and finally connecting a polystyrene transparent shell to protect the chip, the shell comprising columns connecting the inlet and outlet holes.

[0049] The chip is used in conjunction with a PD-L1-positive CTCs detection kit; the kit includes a PD-L1 aptamer reagent and a CD45 / PanCK / PD-L1 antibody combination labeled with fluorescein.

[0050] In this chip, the modified Epcam antibody captures single intact CTC cells, and the cell fluorescence image is obtained by immunofluorescence staining. Then, the channel is incubated with a specific aptamer to recognize and bind to the PD-L1 membrane protein on the CTC surface or the free PD-L1 protein, and the microfluidic end releases the initiator chain, which causes a primer exchange reaction (PER) under the action of the enzyme, produces a large number of amplification products, and activates the CRISPR / Cas12a cleavage reporter group, which is finally quantified by a fluorescence spectrometer.

[0051] Example 2

[0052] A microfluidic chip based on dual-mode combined detection of CRISPR-Cas12a and immunofluorescence visualization, the process of using the chip includes:

[0053] Step 1: First, the aptamer chain is hybridized with the promoter chain to prepare the experimental probe, and then the CRISPR / Cas12a system is used to analyze the target.

[0054] The experimental probe was prepared by adding the promoter chain to the buffer of the aptamer with a final ratio (volume ratio) of 1:1, denaturing at 95°C for 5 minutes, and then naturally cooling to room temperature to allow complete hybridization, and then obtaining the probe storage solution.

[0055] The process of analyzing the target includes:

[0056] First, the aptamer / promoter probe was incubated with different concentrations of H1299 tumor cells.

[0057] Next, the supernatant was taken for primer exchange (PER) reaction.

[0058] Finally, the CRISPR / Cas12a system was activated.

[0059] Simply put, the aptamer / promoter probe solution is injected into the chip and incubated with circulating epithelial tumor cells separated by the microfluidic system for different periods of time. The mixed solution after incubation is taken and added to the CRISPR-Cas12a reaction system, and the fluorescence intensity of the reaction solution is measured.

[0060] Step 2: The protein expression level of PD-L1 in the cells was detected by immunoblotting (WB) and the fluorescence intensity of PD-L1 in the cells was detected by BioINK reagent staining.

[0061] Step 3, identifying the cells captured in the chip by immunofluorescence staining, the process is as follows:

[0062] Add 150 μl (microliter) of cell fixative to the chip, incubate at room temperature for 15 minutes, slowly wash the chip twice with phosphate buffer to remove the residual cell fixative, and then take 1 μl of Pan CK-FITC, CD45-APC and PD-L1-Cy5.5 direct-labeled antibodies respectively, mix with 147 μl of dye diluent and inject into the chip, incubate in a wet box in the dark for 1 hour, then slowly wash the chip twice, absorb the nuclear dye and mix with phosphate buffer and inject into the chip to incubate in the dark for 10 minutes, and then slowly wash the chip twice again, use a fluorescence microscope to acquire images along the designated focus surface, and perform cell image acquisition, counting and analysis.

[0063] Under a fluorescence microscope, it was observed that circulating epithelial cells had complete cell morphology under bright field, and the nuclear-cytoplasmic ratio was consistent with the characteristics of tumor cells; under a fluorescence microscope, the cell nucleus was blue and the cell membrane was green, which indicated that PanCK was positive, indicating circulating epithelial tumor cells; the cell nucleus was blue and the cell membrane was orange, which indicated that CD45 was positive, indicating that it was a white blood cell; the cell nucleus was blue and the cell membrane was green and red, indicating that it was PD-L1 + CTCs.

[0064] Step 4: Draw the receiver operating characteristic (ROC) curve to explore the sensitivity and specificity of the microfluidic analysis system to capture and CRISPR / Cas12a to quantitatively diagnose the PD-L1 positive expression level of non-small cell lung cancer (NSCLC).

[0065] Example 3

[0066] A microfluidic chip based on dual-mode combined detection of CRISPR-Cas12a and immunofluorescence visualization. The channel structure of the microfluidic system and the CTC capture process are shown in Figure 1 shown.

[0067] The chip integrates immunofluorescence visualization into the microfluidic system and designs a channel for dual-mode PD-L1 protein signal detection and analysis. The system is mainly composed of a serpentine channel (200μl) and an inlet and outlet (350μl). The serpentine channel extends the flow path to avoid CTC blockage. The microcolumn array in the channel is modified with a sufficient amount of biotin-modified capture antibody Epcam, which can be directly connected to the chip for capturing CTCs. The chip should be stored at 4°C after streptomycin modification. The other PD-L1-specific aptamer is freshly pre-prepared and injected into the chip channel. When the peripheral blood mononuclear cells are separated by microfluidics and enter the chip for incubation, the overall expression level of the patient's PD-L1-positive CTC is obtained, achieving efficient and coordinated capture and detection.

[0068] Example 4

[0069] The NUPACK analysis method is used to model the secondary structure of oligonucleotides and duplexes and is used for targeted, released and catalyzed hairpin amplification systems. Figure 2 shown.

[0070] In the application of PD-L1 positive circulating tumor cells in the peripheral blood of NSCLC patients, the sequence of the PD-L1 aptamer shown as a preferred embodiment is as follows.

[0071] SEQ ID NO.1:

[0072] ACGGGCCACATCAACTCATTGATAGACAATGCGTCCACTGCCCGT.

[0073] NUPACK is an evolving software suite developed at Caltech that serves researchers in the fields of nucleic acid nanotechnology, molecular programming, synthetic biology, and the broader life sciences to analyze and design nucleic acid structures, devices, and systems.

[0074] Example 5

[0075] Agarose gel electrophoresis is a standard method for separating, identifying, and purifying DNA fragments. Figure 3 shown.

[0076] In the figure, M: DNA molecule marker lane; L1: PD-L1 aptamer; L2: promoter; L3: PD-L1 aptamer + promoter; L4: hairpin; L5: synthetic product E; L6: DNA product after synthetic product E triggers PER; L7: ssDNA; L8 and L9: ssDNA is degraded by CRISPR / Cas12a with or without E.

[0077] Since the HP hairpin can bind to another primer, thereby inducing the next round of PER and eventually synthesizing a large amount of EP, a new band was observed at the top of lane 6, which can be explained as the occurrence of PER production of extension products by E using HP as a catalytic template for primer exchange reaction. In addition, the disappearance of the ssDNA band in lane L8 can be attributed to the cleavage of Cas12a / crRNA. In contrast, the absence of E in L9 cannot induce PER or Cas12a activation.

[0078] Example 6

[0079] The fluorescence spectra obtained by the reaction system established in the present invention under different reagent combination conditions are shown in Figure 4 shown.

[0080] The figure shows the peak results of fluorescence spectra under different conditions, indicating that even after the aptamer / promoter is mixed with the hairpin, the Cas12a / crRNA complex cannot be activated with the assistance of the enzyme.

[0081] Only when short single-stranded DNA, adaptor / promoter and polymerase are present at the same time can a highest peak be observed, indicating that the extension product after PER can be used to activate the trans-cleavage activity of CRISPR / Cas12a.

[0082] Example 7

[0083] The protein expression level of PD-L1 in cells was detected by Western blotting (WB). The expression level of PD-L1 protein in normal lung epithelial BEAS-2B (human bronchial epithelial cells) and 6 NSCLC cell lines can be found in Figure 5 As shown in A.

[0084] BioINK staining shows the expression levels of PD-L1 in different NSCLC cell lines, PD-L1 positive and negative control cells. Figure 5 As shown in B.

[0085] Except for BEAS-2B, the IF (immunofluorescence) staining intensity of all NSCLC cell lines was higher than the negative control fluorescence value, among which the IF mean values ​​of H1299, A549, and H1975 were significantly higher than the PD-L1 negative control. Compared with the PD-L1 negative control, the IF intensity difference of the H1299 cell line with high PD-L1 expression was greater than 10 times, indicating that the dynamic range of fluorescence detection was wide, ensuring high sensitivity of CTC detection with low to high levels of PD-L1 expression.

[0086] Example 8

[0087] Fluorescence intensity and PD-L1 +For a graph showing a linear increase in the logarithmic value of CTCs concentration, see Figure 6 shown.

[0088] Using the H1299 cell line as the verification object, different concentrations of PD-L1-positive H1299 were quantitatively analyzed. The binding of the PD-L1 adaptor to CTC increased the release of the Initiator chain, and then formed abundant EP chains, thereby effectively activating Cas12a and cutting single-stranded ssDNA-F to restore fluorescence.

[0089] As the cell concentration gradually increased from 20 to 10 7 cell / mL, the fluorescence intensity collected at 520nm gradually increased. It was found that the fluorescence intensity increased linearly with the increase of the logarithmic value of CTC concentration, and the equation I = 363.946 × LogC-26.258 (R 2 =0.998) and the detection limit was 2.2 cell / mL, both of which were lower than those of previously reported detection methods.

[0090] Example 9

[0091] The chip captures the staining patterns of white blood cells (WBC) and circulating tumor cells (CTC) in the peripheral blood of NSCLC patients. Figure 7 shown.

[0092] The microfluidic chip of the present invention successfully captures CTCs and performs immunofluorescence staining to distinguish PanCK-positive circulating tumor cells (CTCs) and CD45-positive white blood cells (WBCs) in peripheral blood, blue: cell nucleus, orange: CD45 (white blood cells), green: PanCK (CTC), bright field: cells.

[0093] See the example of CTC staining for capturing PD-L1(-) and different degrees of PD-L1(+) in the peripheral blood of NSCLC patients on chip. Figure 8 Blue: cell nucleus, orange: CD45 (leukocytes), green: PanCK (CTC), red: PD-L1, bright field: cells.

[0094] Example 10

[0095] The integrated microfluidic analysis system of the present invention captures and quantitatively analyzes PD-L1 with CRISPR / Cas12a + CTCs and prediction of diagnostic performance can be found in Fig. 9 shown.

[0096] Quantification of PD-L1 by CRISPR / Cas12a + CTCs, Fig. 9A. The distribution of the scatter plot of clinical sample detection shows that the cut off value is 96.11, including healthy people (n=30) and NSCLC (n=30); the confusion matrix shows that the CRISPR / Cas12a quantitative method has a good prediction performance; Fig. 9 B The quantitative diagnostic ability of CRISPR / Cas12a was evaluated by ROC and AUC = 0.929 was obtained, which has a very high clinical diagnostic value.

[0097] The present invention provides a microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection in detecting PD-L1 in the peripheral blood of NSCLC patients. + Application in CTCs. The chip consists of three layers, the bottom layer is a microscope slide, the surface of the PDMS block with microchannels and slides is treated with plasma, one side is inlaid and bonded to the slide, and finally the polystyrene transparent shell protecting the chip is connected, the shell includes a cylinder connecting the inlet and outlet holes. Through the micro-sites coated with Epcam antibodies arranged on the surface of the microarray inside the chip, the antibodies bind to CTCs and adhere to the chip to achieve efficient capture of circulating tumor epithelial cells. In addition, a PD-L1 positive CTCs detection kit is provided, which includes a PD-L1 aptamer reagent and a CD45 / PanCK / PD-L1 antibody combination labeled with fluorescein. The present invention designs a dual-mode detection for PD-L1 positive CTCs for the first time. PD-L1 is an important indicator for the diagnosis and prediction of immunotherapy for NSCLC patients. By preparing a dual-mode microfluidic chip, PD-L1 positive CTCs are efficiently and conveniently enriched and detected, which can facilitate clinical non-invasive and accurate prediction of PD-L1 expression and immunotherapy efficacy monitoring and prognosis in NSCLC patients.

[0098] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode joint detection, characterized in that: The microfluidic chip consists of three layers: the bottom layer is a microscope slide, the middle layer is a PDMS block with microchannels and a slide, and the top layer is a polystyrene transparent shell that protects the chip. The microchannels inside the chip are equipped with a microarray, and the surface is arranged with microsites coated with Epcam antibodies. The antibodies bind to CTCs and adhere to the chip, achieving efficient capture of circulating epithelial tumor cells.

2. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 1, characterized in that, The chip is prepared by treating the surface of a PDMS block with microchannels and a glass slide with plasma, then embedding and bonding one side of the chip on the bottom glass slide, and finally connecting a polystyrene transparent shell to protect the chip, the shell including a column connecting the inlet and outlet holes.

3. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 2, characterized in that, The chip is used in conjunction with a PD-L1 positive CTCs detection kit; the kit includes a PD-L1 aptamer reagent and a CD45 / PanCK / PD-L1 antibody combination labeled with fluorescein.

4. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 3, characterized in that, In the chip, the modified Epcam antibody captures a single intact CTC cell, and the cell fluorescence image is obtained by immunofluorescence staining and positioning; the channel is then incubated with a specific aptamer to recognize and bind to the PD-L1 membrane protein on the CTC surface or the free PD-L1 protein, and the microfluidic end is collected to release the initiator chain, which causes a primer exchange reaction under the action of the enzyme, generates an amplification product that activates the CRISPR / Cas12a cleavage reporter group, and is finally quantified by a fluorescence spectrometer.

5. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 4, characterized in that, When the chip is used, the aptamer chain is first hybridized with the promoter chain to prepare an experimental probe, and then the CRISPR / Cas12a system is used to analyze the target.

6. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 5, characterized in that, The analysis target is to inject the aptamer / promoter probe solution into the chip, incubate it with circulating epithelial tumor cells separated by the microfluidic system for different time periods, take the incubated mixture, add the CRISPR-Cas12a reaction system, and measure the fluorescence intensity of the reaction solution.

7. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 3, characterized in that, The chip, when in use, also includes identifying the cells captured in the chip by immunofluorescence staining.

8. The microfluidic chip based on dual-mode combined detection of CRISPR-Cas12a and immunofluorescence visualization as claimed in claim 7, characterized in that, The identification process is as follows: add cell fixative to the chip, incubate at room temperature, wash the chip with buffer, remove residual cell fixative, take Pan CK-FITC, CD45-APC and PD-L1-Cy5.5 direct labeling antibodies respectively, mix them with dye diluent and inject them into the chip, incubate in a wet box away from light, then wash the chip, absorb the nuclear dye and mix them with buffer and inject them into the chip for incubation in the dark, wash the chip again, and use a fluorescence microscope to obtain images along the specified focus surface to collect, count and analyze cell images.

9. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 8, characterized in that, The chip, through a fluorescence microscope, observed that the circulating epithelial cells had complete cell morphology under bright field, and the nuclear-cytoplasmic ratio was consistent with the characteristics of tumor cells; the cell nucleus was blue and the cell membrane was green under the fluorescence microscope, that is, PanCK expression was positive, indicating circulating epithelial tumor cells; the cell nucleus was blue and the cell membrane was orange, that is, CD45 expression was positive, indicating white blood cells; the cell nucleus was blue and the cell membrane was green and red fluorescence, indicating PD-L1 + CTCs.

10. The microfluidic chip based on CRISPR-Cas12a and immunofluorescence visualization dual-mode combined detection as claimed in claim 9, characterized in that, The chip, when used, also includes drawing a receiver operating curve to explore the sensitivity and specificity of the microfluidic analysis system in capturing and CRISPR / Cas12a in quantitatively diagnosing the positive expression of PD-L1 in non-small cell lung cancer.

Citation Information

Patent Citations

  • Circulating tumor cell detection kit and application thereof

    CN105785005A

  • Compositions and methods for immunotherapy targeting FLT3, PD-1, and / or PD-l1

    CN112673093A

  • Method for simultaneously detecting activity and immune state of peripheral blood gastric cancer circulating tumor cells

    CN115792245A

  • Fluorescent biosensor for detecting exosome based on CRISPR-Cas system

    CN116103374A

  • Integrated sensor for separating extracellular vesicles and detecting membrane proteins of extracellular vesicles

    CN116990525A

Cited By

  • Micro-fluidic chip for constructing tumor microenvironment based on multiple markers and application of micro-fluidic chip

    CN120009525A